Eckert & Ziegler SE manufactures and sells isotope technology components worldwide. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of uveal melanomas; brain seed, HDR and brachytherapy; ophthalmological products; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceuticals, laboratory equipment, radiosynthesis equipment, quality-control equipment, consumables, therapeutic products and plant engineering, and other services. It offers standard and radiation sources for medical and industrial sectors; medical imaging and spect diagnostics, industrial analytical and instrument, high activity CS-137 and CO-60, and oil well logging sources; blood irradiators and environmental disposal source services; and bulk isotopes as well as calibration related sources for radioisotopes. It serves medical, scientific, and industrial applications. The company was formerly known as Eckert & Ziegler Strahlen- und Medizintechnik AG and changed its name to Eckert & Ziegler SE in March 2024. Eckert & Ziegler SE was founded in 1992 and is headquartered in Berlin, Germany.
Metrics to compare  | EUZG  | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies  | Relationship RelationshipEUZGPeersSector  | |
|---|---|---|---|---|
P/E Ratio  | 25.1x | 17.0x | −0.6x | |
PEG Ratio  | 3.00 | 0.16 | 0.00 | |
Price/Book  | 4.6x | 2.0x | 2.6x | |
Price / LTM Sales  | 3.5x | 1.5x | 3.4x | |
Upside (Analyst Target)  | 35.0% | 29.2% | 39.1% | |
Fair Value Upside  | Unlock | 24.1% | 5.8% | Unlock |